非臨床試験市場- 世界の産業規模、シェア、動向、機会、予測、試験タイプ別、試験別、治療領域別、エンドユーザー別、地域別、競合別セグメント、2020-2030年

非臨床試験の世界市場規模は2024年に113億6,000万米ドルで、予測期間には169億5,000万米ドルに達すると予測され、2030年までのCAGRは6.87%です。

非臨床試験の世界市場は、製薬・ヘルスケア産業のダイナミックかつ不可欠な構成要素であり、新薬や医療機器の開発・承認において極めて重要な役割を果たしています。この市場には、潜在的な治療や治療法が人体実験される前に行われる幅広い活動が含まれます。非臨床試験は、前臨床試験と呼ばれることが多く、実験薬および医薬品の安全性、有効性、毒性を評価するために、動物、in vitroシステム、またはコンピューターシミュレーションで実施される一連の厳格なテストと評価が含まれます。世界の非臨床試験市場成長の主な促進要因の一つは、無数の健康状態や疾病に対処するための革新的な医薬品や医療機器に対する需要が増え続けていることです。その結果、製薬会社やバイオテクノロジー会社、学術研究機関は、自社製品が規制基準を満たし、ヒトに安全に使用できることを保証するために、非臨床試験に多大な投資を行っています。このため、非臨床試験サービスを専門の開発業務受託機関（CRO）に委託する動きが急増し、市場の拡大に拍車をかけています。

市場概要
予測期間	2026-2030
市場規模：2024年	113億6,000万米ドル
市場規模：2030年	169億5,000万米ドル
CAGR：2025年～2030年	6.87%
急成長セグメント	製薬・バイオテクノロジー企業
最大市場	北米

市場促進要因

革新的な医薬品と医療機器に対する需要の高まり

主な市場課題

厳しい規制遵守

主要市場動向

革新的治療法の台頭

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 世界の非臨床試験市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 研究タイプ別（薬力学（PD）研究、薬物動態（PK）研究、毒性学研究）
  • テスト別（In silico、In vitro、In vivo）
  • 治療領域別（腫瘍学、循環器学、神経学、免疫学、その他）
  • エンドユーザー別（製薬会社、バイオテクノロジー企業、開発調査受託機関（CRO）、学術機関および政府調査機関、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ
  • 研究タイプ別
  • テスト別
  • 治療領域別
  • エンドユーザー別
  • 地域別

第5章 アジア太平洋地域の非臨床試験市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 研究タイプ別
  • テスト別
  • 治療領域別
  • エンドユーザー別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第6章 欧州の非臨床試験市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第7章 北米の非臨床試験市場展望

• 市場規模・予測
• 市場シェア・予測
  • 研究の種類
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第8章 南米の非臨床試験市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第9章 中東・アフリカの非臨床試験市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第10章 市場力学

• 促進要因
• 課題

第11章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第12章 世界の非臨床試験市場：SWOT分析

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Labcorp Drug Development
• Charles River Laboratories
• PPD（Pharmaceutical Product Development）
• ICON plc
• Novartis AG
• Merck & Co., Inc.
• AstraZeneca plc
• CMIC HOLDINGS Co., LTD
• ProPharma
• MorphoSys AG

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Non-Clinical Trials Market was valued at USD 11.36 Billion in 2024 and is expected to reach USD 16.95 Billion in the forecast period with a CAGR of 6.87% through 2030. The Global Non-Clinical Trials Market represents a dynamic and essential component of the pharmaceutical and healthcare industries, playing a pivotal role in the development and approval of new drugs and medical devices. This market encompasses a wide range of activities that occur before a potential treatment or therapy is tested on human subjects. Non-clinical trials, often referred to as preclinical trials, involve a series of rigorous tests and evaluations conducted on animals, in vitro systems, or computer simulations to assess the safety, efficacy, and toxicity of experimental drugs and medical products. One of the key drivers behind the growth of the global non-clinical trials market is the ever-increasing demand for innovative pharmaceuticals and medical devices to address a myriad of health conditions and diseases. As a result, pharmaceutical and biotechnology companies, as well as academic research institutions, are heavily invested in non-clinical trials to ensure that their products meet regulatory standards and are safe for human use. This has led to a surge in the outsourcing of non-clinical trial services to specialized contract research organizations (CROs), further fueling market expansion.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 11.36 Billion
Market Size 2030	USD 16.95 Billion
CAGR 2025-2030	6.87%
Fastest Growing Segment	Pharmaceutical and Biotechnology Companies
Largest Market	North America

Key Market Drivers

Rising Demand for Innovative Pharmaceuticals and Medical Devices

The global demand for innovative pharmaceuticals and medical devices is a primary driver behind the robust growth of the Global Non-Clinical Trials Market. As the global population ages and the prevalence of chronic diseases continues to escalate, there is an increasing need for cutting-edge therapies and medical solutions. This burgeoning demand has propelled pharmaceutical and biotechnology companies, as well as academic research institutions, into an intense race to develop new drugs and devices that address a wide spectrum of health conditions.

Non-clinical trials, also known as preclinical trials, are instrumental in meeting this demand by providing a crucial testing ground for these innovative products before they advance to human clinical trials. These trials involve comprehensive assessments of safety, efficacy, and toxicity, which are essential for regulatory approval and eventual market access. In 2023, research and development spending in the pharmaceutical industry exceeded USD 300 billion globally, highlighting the industry's commitment to innovation and the critical role of non-clinical trials in the drug development process.

Key Market Challenges

Stringent Regulatory Compliance

Complex and Evolving Regulations: Regulatory agencies, such as the FDA in the United States and the EMA in Europe, have developed comprehensive guidelines that govern non-clinical trials. However, these regulations are intricate, subject to frequent updates, and can vary from one region to another. Navigating this complex regulatory landscape demands substantial expertise and resources, which can slow down the initiation and progression of non-clinical trials. Stringent Data and Documentation Requirements: Regulatory authorities require extensive documentation and data to support non-clinical trial submissions. Researchers must meticulously document every aspect of the trial, from study design and procedures to results and statistical analyses. This demanding documentation process can be time-consuming and resource-intensive, diverting valuable time and resources away from research activities.

Ethical and Patient Safety Considerations: Regulatory compliance often entails rigorous ethical considerations and a focus on patient safety. These ethical standards necessitate adherence to guidelines that protect the welfare of research subjects, whether they are animals or humans. Ensuring compliance with these ethical standards can lead to additional hurdles and delays, particularly when addressing the safety and well-being of trial participants. Meeting regulatory compliance requirements is resource-intensive. Companies and research organizations must invest in state-of-the-art facilities, skilled personnel, and advanced technologies to conduct non-clinical trials that satisfy regulatory standards.

Key Market Trends

Rise in Innovative Therapies

The Global Non-Clinical Trials Market is experiencing a substantial boost due to the relentless rise in demand for innovative therapies. As the global population grapples with an increasing burden of diseases, there has been an unmistakable call for transformative pharmaceuticals and medical devices to address these health challenges. This insatiable demand for groundbreaking treatments has spurred pharmaceutical and biotechnology companies, as well as academic research institutions, to intensify their research and development efforts. Consequently, non-clinical trials have taken center stage as a pivotal phase in the development of these innovative therapies.

In the current landscape, innovative therapies encompass a wide spectrum of cutting-edge approaches, including precision medicine, gene therapies, immunotherapies, and targeted therapeutics, among others. These novel treatments hold the promise of offering highly effective and personalized solutions for a range of health conditions, from rare genetic disorders to complex cancers. However, before these therapies can advance to human clinical trials and eventually reach patients, they must undergo rigorous assessment in non-clinical trials.

Key Market Players

• Labcorp Drug Development
• Charles River Laboratories
• PPD (Pharmaceutical Product Development)
• ICON plc
• Novartis AG
• Merck & Co., Inc.
• AstraZeneca plc
• Cmic Holdings Co., Ltd
• ProPharma
• MorphoSys AG

Report Scope:

In this report, the Global Non-Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Clinical Trials Market, By Study Type:

• Pharmacodynamics (PD) studies
• Pharmacokinetics (PK) studies
• Toxicology studies

Non-Clinical Trials Market, By Test:

• In silico
• In vitro
• In vivo

Non-Clinical Trials Market, By Therapeutic Area:

• Oncology
• Cardiovascular
• Neurology
• Immunology
• Others

Non-Clinical Trials Market, By End User:

• Pharmaceutical and Biotechnology Companies
• Contract Research Organizations (CROs)
• Academic and Government Research Institutes
• Others

Non-Clinical Trials Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Non-Clinical Trials Market.

Available Customizations:

Global Non-Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Non-Clinical Trials Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Study Type (Pharmacodynamics (PD) studies, Pharmacokinetics (PK) studies, Toxicology studies)
  • 4.2.2. By Test (In silico, In vitro, In vivo )
  • 4.2.3. By Therapeutic Area (Oncology, Cardiovascular, Neurology, Immunology, Others)
  • 4.2.4. By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Academic and Government Research Institutes, Others )
  • 4.2.5. By Region
  • 4.2.6. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Study Type
  • 4.3.2. By Test
  • 4.3.3. By Therapeutic Area
  • 4.3.4. By End User
  • 4.3.5. By Region

5. Asia Pacific Non-Clinical Trials Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Study Type
  • 5.2.2. By Test
  • 5.2.3. By Therapeutic Area
  • 5.2.4. By End User
  • 5.2.5. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Non-Clinical Trials Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Study Type
      • 5.3.1.2.2. By Test
      • 5.3.1.2.3. By Therapeutic Area
      • 5.3.1.2.4. By End User
  • 5.3.2. India Non-Clinical Trials Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Study Type
      • 5.3.2.2.2. By Test
      • 5.3.2.2.3. By Therapeutic Area
      • 5.3.2.2.4. By End User
  • 5.3.3. Australia Non-Clinical Trials Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Study Type
      • 5.3.3.2.2. By Test
      • 5.3.3.2.3. By Therapeutic Area
      • 5.3.3.2.4. By End User
  • 5.3.4. Japan Non-Clinical Trials Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Study Type
      • 5.3.4.2.2. By Test
      • 5.3.4.2.3. By Therapeutic Area
      • 5.3.4.2.4. By End User
  • 5.3.5. South Korea Non-Clinical Trials Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Study Type
      • 5.3.5.2.2. By Test
      • 5.3.5.2.3. By Therapeutic Area
      • 5.3.5.2.4. By End User

6. Europe Non-Clinical Trials Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Study Type
  • 6.2.2. By Test
  • 6.2.3. By Therapeutic Area
  • 6.2.4. By End User
  • 6.2.5. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Non-Clinical Trials Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Study Type
      • 6.3.1.2.2. By Test
      • 6.3.1.2.3. By Therapeutic Area
      • 6.3.1.2.4. By End User
  • 6.3.2. Germany Non-Clinical Trials Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Study Type
      • 6.3.2.2.2. By Test
      • 6.3.2.2.3. By Therapeutic Area
      • 6.3.2.2.4. By End User
  • 6.3.3. Spain Non-Clinical Trials Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Study Type
      • 6.3.3.2.2. By Test
      • 6.3.3.2.3. By Therapeutic Area
      • 6.3.3.2.4. By End User
  • 6.3.4. Italy Non-Clinical Trials Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Study Type
      • 6.3.4.2.2. By Test
      • 6.3.4.2.3. By Therapeutic Area
      • 6.3.4.2.4. By End User
  • 6.3.5. United Kingdom Non-Clinical Trials Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Study Type
      • 6.3.5.2.2. By Test
      • 6.3.5.2.3. By Therapeutic Area
      • 6.3.5.2.4. By End User

7. North America Non-Clinical Trials Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Test
  • 7.2.2. Study Type
  • 7.2.3. By End User
  • 7.2.4. By Therapeutic Area
  • 7.2.5. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Non-Clinical Trials Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Study Type
      • 7.3.1.2.2. By Test
      • 7.3.1.2.3. By Therapeutic Area
      • 7.3.1.2.4. By End User
  • 7.3.2. Mexico Non-Clinical Trials Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Study Type
      • 7.3.2.2.2. By Test
      • 7.3.2.2.3. By Therapeutic Area
      • 7.3.2.2.4. By End User
  • 7.3.3. Canada Non-Clinical Trials Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Study Type
      • 7.3.3.2.2. By Test
      • 7.3.3.2.3. By Therapeutic Area
      • 7.3.3.2.4. By End User

8. South America Non-Clinical Trials Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Study Type
  • 8.2.2. By Test
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Non-Clinical Trials Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Study Type
      • 8.3.1.2.2. By Test
      • 8.3.1.2.3. By Therapeutic Area
      • 8.3.1.2.4. By End User
  • 8.3.2. Argentina Non-Clinical Trials Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Study Type
      • 8.3.2.2.2. By Test
      • 8.3.2.2.3. By Therapeutic Area
      • 8.3.2.2.4. By End User
  • 8.3.3. Colombia Non-Clinical Trials Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Study Type
      • 8.3.3.2.2. By Test
      • 8.3.3.2.3. By Therapeutic Area
      • 8.3.3.2.4. By End User

9. Middle East and Africa Non-Clinical Trials Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Study Type
  • 9.2.2. By Drug Type
  • 9.2.3. By Therapeutic Area
  • 9.2.4. By End User
  • 9.2.5. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Non-Clinical Trials Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Study Type
      • 9.3.1.2.2. By Test
      • 9.3.1.2.3. By Therapeutic Area
      • 9.3.1.2.4. By End User
  • 9.3.2. Saudi Arabia Non-Clinical Trials Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Study Type
      • 9.3.2.2.2. By Drug Type
      • 9.3.2.2.3. By Therapeutic Area
      • 9.3.2.2.4. By End User
  • 9.3.3. UAE Non-Clinical Trials Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Study Type
      • 9.3.3.2.2. By Test
      • 9.3.3.2.3. By Therapeutic Area
      • 9.3.3.2.4. By End User

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Non-Clinical Trials Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Labcorp Drug Development
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Charles River Laboratories
• 14.3. PPD (Pharmaceutical Product Development)
• 14.4. ICON plc
• 14.5. Novartis AG
• 14.6. Merck & Co., Inc.
• 14.7. AstraZeneca plc
• 14.8. CMIC HOLDINGS Co., LTD
• 14.9. ProPharma
• 14.10.MorphoSys AG

15. Strategic Recommendations

16. About Us & Disclaimer